{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:55:28Z","timestamp":1789584928173,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is a rare but well-recognized complication of treatment with antiresorptive agents. Medication-related osteonecrosis of the external auditory canal (MROEAC), on the other hand, is even rarer and mostly reported during bisphosphonate exposure. Its pathophysiology is thought to involve complex multifactorial processes, including inhibition of bone remodeling, altered angiogenesis, infection, and inflammation. Due to the poor recognition of MROEAC, ear canal health is not routinely discussed with patients, and there is no requirement for auditory canal assessment prior to antiresorptive therapy. We present 2 cases of denosumab-associated MROEAC: a 72-yr-old woman with osteoporosis treated with denosumab for 5\u00a0yr (Case A), and an 84-yr-old man with osteoporosis treated with denosumab for 6\u00a0yr (Case B), both of whom presented with unilateral ear itch and were subsequently diagnosed with MROEAC. Both patients were managed conservatively with topical corticosteroid, antimicrobial, antifungal ointments, and cessation of denosumab with subsequent elevation of bone turnover markers. In Case A, a course of teriparatide immediately after denosumab cessation did not improve bone erosion. Teriparatide was ceased due to patient\u2019s concern with renal calculi, high bone resorption markers, and vertebral fracture. A trial of risedronate was commenced with reduction of bone markers and epithelization of the auditory canal. In Case B, risedronate was commenced with reduction of bone markers and early healing of the auditory canal at 4\u00a0mo. Osteonecrosis of sites other than the jaw should be considered a potential rare complication and balanced against the bone protection benefits of long-term antiresorptive therapy. The optimal treatment strategy for MROAEC remains uncertain. Currently, there is no recommendation for routine auditory canal assessment prior to or during antiresorptive treatment. However, sequencing off established denosumab use with follow-on treatment to mitigate potential rapid bone loss needs to be considered.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf134","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T11:40:14Z","timestamp":1754998814000},"source":"Crossref","is-referenced-by-count":3,"title":["Osteonecrosis of the external auditory canal in two patients on denosumab therapy"],"prefix":"10.1093","volume":"9","author":[{"given":"Holly","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Austin Health , Melbourne, 3084 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Yii","sequence":"additional","affiliation":[{"name":"Department of ENT, Austin Health , Melbourne, 3084 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Mei","family":"Teh","sequence":"additional","affiliation":[{"name":"Department of ENT, Austin Health , Melbourne, 3084 ,","place":["Australia"]},{"name":"Department of Otolaryngology, Head and Neck Surgery, Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University , Clayton, 3168, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erosha","family":"Premaratne","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health , Melbourne, 3084 ,","place":["Australia"]},{"name":"Department of Medicine, University of Melbourne , Melbourne, 3050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9392-6771","authenticated-orcid":false,"given":"Cherie","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Austin Health , Melbourne, 3084 ,","place":["Australia"]},{"name":"Department of Medicine, University of Melbourne , Melbourne, 3050 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"1","key":"2025091915532326800_ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2025091915532326800_ref2","volume-title":"UK: Royal College of Physicians. Medication-Related Osteonecrosis of the Jaw. Guidance for the Oncology Multidisciplinary Team","author":"www.rcp.ac.uk","year":"2019"},{"issue":"2","key":"2025091915532326800_ref3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/scd.12893","article-title":"Medication-related osteonecrosis of the external auditory canal - a rapid review of the literature and relevance to special care dentists","volume":"44","author":"Khan","year":"2024","journal-title":"Spec Care Dentist"},{"issue":"2","key":"2025091915532326800_ref4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/MAO.0b013e31827ca34d","article-title":"Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review","volume":"34","author":"Salzman","year":"2013","journal-title":"Otol Neurotol"},{"issue":"6","key":"2025091915532326800_ref5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.anl.2020.07.007","article-title":"Denosumab-induced osteonecrosis of external auditory canal","volume":"48","author":"Takeda","year":"2021","journal-title":"Auris Nasus Larynx"},{"issue":"2","key":"2025091915532326800_ref6","doi-asserted-by":"publisher","first-page":"luad021","DOI":"10.1210\/jcemcr\/luad021","article-title":"Two cases of external auditory canal osteonecrosis in patients on antiresorptive therapy for osteoporosis","volume":"1","author":"Kumar","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"8","key":"2025091915532326800_ref7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00405-011-1496-z","article-title":"Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study","volume":"268","author":"Froelich","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"2025091915532326800_ref8","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-014-2684-7","article-title":"External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review","volume":"25","author":"Thorsteinsson","year":"2014","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025091915532326800_ref9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1017\/S0022215118000324","article-title":"Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature","volume":"132","author":"McCadden","year":"2018","journal-title":"J Laryngol Otol"},{"issue":"35","key":"2025091915532326800_ref10","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1200\/JCO.2009.23.4468","article-title":"Bisphosphonate-related osteonecrosis of the jaw and left thumb","volume":"27","author":"Longo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025091915532326800_ref11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.amjoto.2016.05.002","article-title":"Bisphosphonate related osteonecrosis of calvarial bone","volume":"37","author":"Prueter","year":"2016","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"2025091915532326800_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2020.102894","article-title":"Malignant otitis externa: an updated review","volume":"42","author":"Trevi\u00f1o Gonz\u00e1lez","year":"2021","journal-title":"Am J Otolaryngol"},{"issue":"8","key":"2025091915532326800_ref13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1286-4579(00)00391-9","article-title":"The oral cavity as a reservoir of bacterial pathogens for focal infections","volume":"2","author":"Gendron","year":"2000","journal-title":"Microbes Infect"},{"issue":"5","key":"2025091915532326800_ref14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","article-title":"Current understanding of the pathophysiology of osteonecrosis of the jaw","volume":"16","author":"Chang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"25","key":"2025091915532326800_ref15","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025091915532326800_ref16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2025091915532326800_ref17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/01455613211053389","article-title":"Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management","volume":"103","author":"Pe\u0159ina","year":"2024","journal-title":"Ear Nose Throat J"},{"issue":"1","key":"2025091915532326800_ref18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/23772484.2017.1350110","article-title":"Bisphosphonate-associated ear canal osteonecrosis: a case report and review of the literature","volume":"2","author":"Takahashi","year":"2017","journal-title":"Acta Oto-Laryngol Case Rep"},{"issue":"Suppl 2","key":"2025091915532326800_ref19","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1017\/S002221511300100X","article-title":"Bisphosphonate-associated osteonecrosis of the external auditory canal","volume":"127","author":"Wickham","year":"2013","journal-title":"J Laryngol Otol"},{"issue":"26","key":"2025091915532326800_ref20","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025091915532326800_ref21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jos.2020.01.012","article-title":"Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): a multicenter retrospective analysis in Japan","volume":"25","author":"Morishita","year":"2020","journal-title":"J Orthop Sci"},{"issue":"6","key":"2025091915532326800_ref22","doi-asserted-by":"publisher","first-page":"e241203","DOI":"10.1136\/bcr-2020-241203","article-title":"Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal","volume":"14","author":"True","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"9999","key":"2025091915532326800_ref23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2025091915532326800_ref24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025091915532326800_ref25","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.bjoms.2013.02.013","article-title":"Bisphosphonate-associated osteonecrosis of the auditory canal","volume":"51","author":"Kharazmi","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2025091915532326800_ref26","article-title":"Otitis externa","volume":"2015","author":"Hajioff","year":"2015","journal-title":"BMJ Clin Evid"},{"issue":"11","key":"2025091915532326800_ref27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S2213-8587(18)30292-4","article-title":"Osteoporosis: a roadmap to close the treatment gap","volume":"6","author":"The Lancet Diabetes Endocrinology","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf134\/64075236\/ziaf134.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf134\/64075236\/ziaf134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf134\/64075236\/ziaf134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:53:29Z","timestamp":1758311609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf134\/8237221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf134","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,18]]},"article-number":"ziaf134"}}